Recently, the gene for a novel mammalian hematopoietic growth factor homologous to murine interleukin 3 was isolated from a gibbon T cell line and expressed in monkey COS cells.
gibbon cDNA clone was used to obtain the human homologue from a human genomic library. DNA sequence analysis revealed that the coding regions of the primate and human multi-CSF genes are 96% homologous and that both genes share significant homology, particularly with the promotor sequences encoding murine Murine IL-3 has been shown by a number of investigators to have a broad spectrum of biological activities when tested with a variety ofdifferent murine hematopoietic cells as targets (2) . The murine factor has been shown to (a) induce the expression of 20-alpha-hydroxysteroid dehydrogenase in the splenic lymphocytes of nude mice (3); (b) support the proliferation of mast cells (4) and multi-CSF-dependent cell lines (5); (c) induce self generation of pluripotent stem cells (6) ; (d) and in semi-solid medium support the formation of colonies derived from multipotent, erythroid, granulocytic, macrophage, eosinophil, and megakaryocyte progenitors (7, 8) . The discovery of a primate hematopoietin that is structurally related to murine IL3 raises the important question of a functional relationship between the two species. In preliminary experiments, the recombinant gibbon multi-CSF proved to be capable of supporting the growth of human erythroid and myeloid colonies (1) . In this study, we analyze in detail the range of human hematopoietic progenitors that are responsive to the multi-CSF for purposes of comparison with the known biological activities of murine IL-3. Secondly, we report a comparison of the colony types obtained from human progenitor cultures established in the presence of the multi-CSF with those obtained from similar cultures established in the presence of either recombinant human granulocyte-macrophage CSF (GM-CSF) or 
recombinant human granulocyte CSF (G-CSF).
Finally, we analyze the types of colonies found in cultures grown in the presence of a mixture of multi-CSF and either GM-CSF or G-CSF.
Methods
Recombinant gibbon multi-CSF. The plasmid pCSF-MLA, which was originally identified by functional expression cloning, was used to transfect monkey cos-I cells as described previously (9) . This plasmid directs the high level expression of the gibbon multi-CSF in the cos-1 cell system. Conditioned medium from these transfections typically supports the half-maximal proliferation ofprimary blasts from chronic myelogenous leukemia patients at a final dilution between 1:5,000 and 1:50,000. Mock conditioned medium from cos-l cells transfected with vector (pXM) DNA was prepared for use as a negative control.
Recombinant human GM-CSF. Highly purified GM-CSF was kindly provided by the Pilot Development Laboratory of the Genetics Institute. This preparation was prepared from medium conditioned by a Chinese hamster ovary cell line engineered to produce high levels of human GM-CSF (10) and had a specific activity of 1-4 X 106 U/mg in the chronic myelogenous leukemia blast proliferation assay (1).
Recombinant human G-CSF. Several different investigators have
reported the molecular cloning of the human cDNA-encoding G-CSF (11, 12) . Two synthetic oligonucleotides were prepared (21 mers), one with an ATGGCTGGACCTGCCACCCAG sequence and the other an CTCCTGGAGGCCCTGGAAGGG one, which exactly corresponded to two different sequences of the G-CSF cDNA (nucleotides 33-53 and 392-412 in Fig. 1 of Nagata et al. [11] ). These oligonucleotides were used as hybridization probes to isolate several G-CSF cDNA clones from a library prepared from messenger RNA that was isolated from a human trophoblast cell line, designated TPA-30-l ( were added on day 0, and on day 3 human urinary erythropoietin (Terry Fox Laboratories, Vancouver, British Columbia, Canada) at 2 U/ml was added to the cultures. This source of erythropoietin was identical in its effects to those of recombinant erythropoietin. The final cell concentration was 5 X 103/ml for bone marrow and 1 X 103/ml for fetal liver. Either 1-or 0.5-ml duplicates were plated in 35-mm petri dishes or in flat-bottomed 24-well tissue culture plates (Flow Laboratories, Inc., McLean, VA), respectively, and incubated at 370C in a high humidity 4% C02/95% air incubator. Erythroid burst-forming units (BFU-E), granulocyte, macrophage, granulocyte-macrophage, and eosinophil colony-forming units (CFU-G, CFU-M, CFU-GM and CFU-Eo), and "mixed" colonies comprising erythroblasts and/or granulocytes, macrophages, or eosinophils (CFU-Mix) were counted on day 14. Megakaryocyte CFU (CFU-Meg)
Human plasma from normal donors that had been prescreened for the ability to support the proliferation of CFU-Meg was used. It was obtained from heparmnized blood (10 U/ml) that had been immediately separated by centrifuging at 1,400 rpm for 15 min at 20'C. The plasma was then aspirated and centrifuged at 3,000 rpm for 15 min at 20'C. The platelet-free plasma was filtered and stored at -20'C until required.
Phytohemagglutinin-lymphocyte conditioned medium (PHA-LCM). Phytohemagglutinin-P (Difco Laboratories, Inc., Detroit, MI) was added at 0.15% vol/vol to Ficoll-Paque-separated blood mononuclear cells cultured at 2.5 X 105/ml in IMDM/10% FCS. The conditioned medium was collected at 72 h and stored at -20°C until required.
Enriched bone marrow cells were cultured in a mixture containing 30% human plasma, 5 X I0-' M mercaptoethanol, penicillin-strepto- sponsive to multi-CSF. In addition, GM-CSF is capable of supporting the proliferation of at least some megakaryocytic progenitors (C. M. Niemeyer, C. A. Sieff, unpublished observations). However, in preliminary experiments, we routinely observed greater numbers of erythroid bursts in cultures of bone marrow progenitors grown in the presence of the multi-CSF than those grown in the presence of GM-CSF or with the plateau level achieved with our laboratory standard Mo-CM (Fig. 3) . In this series of four experiments, the multi-CSF at optimal concentrations was found to support the proliferation of approximately 25% more BFU-E-derived colonies than MO-CM while the plateau of erythroid colonies found in the GM-CSF-stimulated cultures was 25% less than that found in the Mo-CM controls. Comparison of these data using either a t-test or the Wilcoxon Rank Sum Test revealed that multi-CSF supports the formation of significantly more erythroid bursts erythroid colony formation, these results distinguish two subpopulations of BFU-E: one that is multi-CSF responsive and another which is responsive to both multi-CSF and GM-CSF. Since the gibbon multi-CSF used in these experiments was not purified to homogeneity, we cannot exclude the rather unlikely possibility that the crude cos-1 cell conditioned medium contained an activity that synergized with the multi-CSF to support colony formation by the first subpopulation of BFU-E. It will be necessary to repeat these experiments with highly purified multi-CSF to confirm that this is a unique function of multi-CSF. A similar analysis of the effects of multi-CSF on CFU-GM progenitors was not possible in these experiments because plateau levels of CFU-GM-derived colonies were often not achieved, even at the highest possible concentrations of the recombinant multi-CSF (data not shown). In our culture system, much lower concentrations of multi-CSF were required to achieve optimal BFIJ-E colony formation than were required for CFU-GM colony formation. Whether this is due to a real difference in responsiveness ofthe two different types of progenitor cells or simply a reflection of suboptimal conditions for growth of CFU-GM colonies is unclear. However, the latter possibility is made less likely by the observation that the GM-CSF dose-response curves for CFU-GM and BFU-E are very similar (data not shown).
In contrast to our results with combined multi-CSF and GM-CSF, we found that inclusion of G-CSF in bone marrow progenitor cell cultures along with multi-CSF resulted in a substantial increase in total colony number relative to the results obtained with the individual factors. The effect was specific for CFU-G-derived colonies: no enhancement of erythroid or macrophage colony formation was observed. The increase in the number of granulocytic colonies was found to exceed the sum of the numbers of CFU-G-derived colonies obtained with the separate factors. This result implies that there may be distinct subsets of granulocytic precursors which respond to multi-CSF, G-CSF, or the combined stimulus. Indeed, in one experiment, CFU-G were individually plucked, and colony size determined by hemocytometer counts. CFU-G contained a mean of400 and 500 cells per multi-CSFor G-CSF-stimulated culture, respectively, while colonies derived from progenitors stimulated by both factors contained a mean of2,800 cells. This may be analogous to the requirement of BFU-E subsets for either burst-promoting activity and erythropoietin or for erythropoietin alone ( 15) . Further work is required to define the growth factor requirements of CFU-G progenitors more precisely.
We have shown that the recombinant gibbon multi-CSF is a potent multilineage hematopoietin active in supporting the proliferation of human progenitor cells. Because of the extensive sequence homology with the human protein, it seems likely that the human multi-CSF will display very similar biological activities. We have recently used the human gene to produce the recombinant human protein to test this expectation (Yang, Y. C., unpublished results). The availability of substantial quantities ofthis factor will soon permit us to begin to analyze the role ofmulti-CSF in regulating hematopoiesis in vivo. Murine multi-CSF has recently been shown to stimulate murine hematopoiesis in vivo (22, 23) . In particular, it will be of great interest to compare the effects of administration of multi-CSF with those already achieved in primates by administration of GM-CSF (24) . We expect that these and the other colony-stimulating factors will soon prove to be useful tools for stimulating hematopoiesis in a variety of clinical settings. 822 Sieffet al.
